The financing of European medical technology is undergoing a structural transition that challenges the viability of its historical funding mechanisms. For decades, early-stage medtech innovation relied on the traditional venture capital model, which was originally pioneered to support the rapid scaling, high gross margins, and predictable, capital-efficient exit pathways of the software industry. However, the combination of physical hardware development timelines, complex and

The Hungarian life sciences, medical technology, and biotechnology sectors represent a highly concentrated, export-driven industry defined by a strong academic foundation and a transition from traditional pharmaceutical manufacturing to advanced digital health, medical deep tech, and artificial intelligence. The sector comprises approximately 150 to 180 export-driven medical device manufacturing enterprises, alongside around 90 biotechnology companies and a broader network of

The European healthcare technology and clinical artificial intelligence sectors have transitioned into an era of disciplined industrialisation. The speculative fragmentation and "growth-at-all-costs" investment thesis that characterized the zero-interest-rate policy era have been replaced by a rigorous focus on unit economics, real-world clinical evidence, and deep workflow integration. As the market approaches the second half of 2026, venture capital deployment in clinical A